La Jolla Pharmaceutical Company (NASDAQ:LJPC)
|
0.090 0.000 (0.00%) Mar 03 - Close |
|
|
|
After-Hours 0.10 0.00 (0.00%) Mar 03 15:59ET
- Compare LJPC with:
- View: Line | Candlestick
Company Profile
La Jolla Pharmaceutical Company
6455 Nancy Ridge Drive
San Diego, CA 92121
United States - Map
Phone: (858) 452-6600
Fax: (858) 452-6893
Website: www.ljpc.com
State of incorporation: Delaware
CEO: Dr. Deirdre Y. Gillespie, M.D.
Employees: 94
Sector: Healthcare
Industry Group: Drugs
Industry: Biotechnology
Res/dev of therapeutics for autoimmune diseases
A biopharmaceutical company that has historically focused on the development and testing of Riquent as a treatment for Lupus nephritis.
Recent news for LJPC
-
La Jolla says shares will be delisted Thursday
AP - Mar 03 at 10:53AM (EST)
-
Business Wire - Mar 03 at 9:11AM (EST)
-
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online - Mar 01 at 5:31PM (EST)
-
La Jolla Pharmaceutical Company Announces the Adjournment of Special Meeting of Stockholders
Business Wire - Mar 01 at 5:29PM (EST)
-
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online - Feb 24 at 2:52PM (EST)
-
Business Wire - Feb 24 at 9:11AM (EST)
-
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online - Feb 19 at 2:28PM (EST)
-
La Jolla Pharmaceutical Company Provides Responses to Frequently Asked Questions about Merger Vote
Business Wire - Feb 19 at 2:20PM (EST)
-
LA JOLLA PHARMACEUTICAL CO Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online - Feb 16 at 2:59PM (EST)
-
Business Wire - Feb 16 at 9:00AM (EST)
